Our Insights
Making AI Work for Your First Launch: Where It Drives Commercial and Medical Impact, and Where It Doesn’t
July 15, 2026
Insight Type: Webinar
View the webinar recording and learn how emerging biopharma companies can evaluate AI investments, identify high-value use cases, avoid common implementation pitfalls, and align AI capabilities with key commercial and medical launch milestones. This session was led by Beghou.
Launch Ready: From Fragmented Launch Data to Agentic Orchestration
June 30, 2026
Insight Type: Webinar
View the webinar recording and discover how first-time launch organizations can coordinate CMOs, 3PLs, and downstream partners by transforming disconnected launch data into integrated, actionable execution. This session was led by Tracelink
Launch Ready: Hiring Your First (or Next) Critical Roles
June 16, 2026
Insight Type: Webinar
View the webinar recording and understand which roles truly matter at different stages of launch readiness, how to prioritize hiring, and how to build a team structured for long-term success. This session was led by AmpersandPeople
Launch Ready: Building Supply Chain Resilience for your First Launch
June 3, 2026
Insight Type: Webinar
View the webinar recording and learn how emerging biopharma companies can design flexible, risk-resistant supply chains that withstand uncertainty while ensuring product availability at launch and beyond. This session was hosted by McKesson 3PL
FTLA Insights – Q1 2026 Summary Edition
Insight Type: Insight
FTLA Insights is designed to move beyond theory and into practice. Each edition shares quarterly summaries of our FTLA
events, webinars, and real-world insights from emerging biopharma companies.
The CRM Decision: Choosing the Right Commercial Foundation
May 21, 2026
Insight Type: Webinar
In this unique session, we explored key considerations when selecting and implementing your first CRM platform, including timing, scalability, and alignment with commercial strategy.
Join the FTLA
A unique, collaborative forum for leaders in emerging biotech companies—from pre-IND to first launch, partnership, or acquisition.
